Literature DB >> 29569103

Acute myeloid leukemia with translocation (1;21).

Ameer Hamza1, Uqba Khan2, Sidrah Khawar2, Daniel Snower3.   

Abstract

Advancement in genetic and molecular biology techniques has greatly helped our understanding of various diseases, especially hematological disorders. We describe a case of primary myelofibrosis (PMF) that transformed into acute myeloid leukemia with a very rare and unusual genetic translocation of (1;21). There are only five reported cases of this translocation in acute myeloid leukemia (AML) or myelodysplastic syndrome but none of them transformed from PMF. This case not only highlights the importance of rare genetic translocations but also provides the natural history of the disease and its poor prognosis. To the best of our knowledge our patient is the first reported case of AML transformed from PMF to have this unique translocation of (1;21).

Entities:  

Keywords:  AML transformation; Acute myeloid leukemia; Primary myelofibrosis; Translocation (1;21)

Mesh:

Year:  2018        PMID: 29569103     DOI: 10.1007/s11033-018-4168-x

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  16 in total

1.  Acute myeloid leukemia associated with variant t(8;21) detected by conventional cytogenetic and molecular studies: a report of four cases and review of the literature.

Authors:  Li Huang; Lynne V Abruzzo; Jose R Valbuena; L Jeffrey Medeiros; Pei Lin
Journal:  Am J Clin Pathol       Date:  2006-02       Impact factor: 2.493

2.  Identification of truncated RUNX1 and RUNX1-PRDM16 fusion transcripts in a case of t(1;21)(p36;q22)-positive therapy-related AML.

Authors:  M-J P L Stevens-Kroef; E F P M Schoenmakers; M van Kraaij; E Huys; S Vermeulen; B van der Reijden; A Geurts van Kessel
Journal:  Leukemia       Date:  2006-06       Impact factor: 11.528

3.  High expression of EVI1 and MEL1 is a compelling poor prognostic marker of pediatric AML.

Authors:  A Jo; S Mitani; N Shiba; Y Hayashi; Y Hara; H Takahashi; I Tsukimoto; A Tawa; K Horibe; D Tomizawa; T Taga; S Adachi; T Yoshida; H Ichikawa
Journal:  Leukemia       Date:  2015-01-08       Impact factor: 11.528

Review 4.  Results of treatment of children with refractory anaemia with excess blasts (RAEB) and RAEB in transformation (RAEBt) in Great Britain 1990-99.

Authors:  David K H Webb; Sarah J Passmore; Ian M Hann; Georgina Harrison; Keith Wheatley; Judith M Chessells
Journal:  Br J Haematol       Date:  2002-04       Impact factor: 6.998

5.  Prdm16 is a physiologic regulator of hematopoietic stem cells.

Authors:  Francesca Aguilo; Serine Avagyan; Amy Labar; Ana Sevilla; Dung-Fang Lee; Parameet Kumar; Ihor R Lemischka; Betty Y Zhou; Hans-Willem Snoeck
Journal:  Blood       Date:  2011-02-22       Impact factor: 22.113

6.  Novel RUNX1-PRDM16 fusion transcripts in a patient with acute myeloid leukemia showing t(1;21)(p36;q22).

Authors:  Ikuya Sakai; Tatsushiro Tamura; Hirosi Narumi; Naoyuki Uchida; Yoshihiro Yakushijin; Takaaki Hato; Shigeru Fujita; Masaki Yasukawa
Journal:  Genes Chromosomes Cancer       Date:  2005-11       Impact factor: 5.006

7.  A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EVI1 gene and is transcriptionally activated in t(1;3)(p36;q21)-positive leukemia cells.

Authors:  N Mochizuki; S Shimizu; T Nagasawa; H Tanaka; M Taniwaki; J Yokota; K Morishita
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

8.  21q22 balanced chromosome aberrations in therapy-related hematopoietic disorders: report from an international workshop.

Authors:  Marilyn L Slovak; Victoria Bedell; Leslie Popplewell; Daniel A Arber; Claudia Schoch; Rosalyn Slater
Journal:  Genes Chromosomes Cancer       Date:  2002-04       Impact factor: 5.006

9.  Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.

Authors:  Alexandre Theocharides; Marjorie Boissinot; François Girodon; Richard Garand; Soon-Siong Teo; Eric Lippert; Pascaline Talmant; Andre Tichelli; Sylvie Hermouet; Radek C Skoda
Journal:  Blood       Date:  2007-03-15       Impact factor: 22.113

10.  CBFA2(AML1) translocations with novel partner chromosomes in myeloid leukemias: association with prior therapy.

Authors:  D Roulston; R Espinosa; G Nucifora; R A Larson; M M Le Beau; J D Rowley
Journal:  Blood       Date:  1998-10-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.